# OnCo record kura-oncology (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/kura-oncology/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "kura-oncology" ;
  schema:name "Kura Oncology"@en ;
  schema:description "Kura Oncology developed ziftomenib, the second menin inhibitor approved for leukaemia (November 2025), in partnership with Kyowa Kirin."@en ;
  schema:url <https://onco.cc/companies/kura-oncology/>, <https://www.kuraoncology.com> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:citation <https://ir.kuraoncology.com/news-releases/news-release-details/kura-oncology-and-kyowa-kirin-announce-fda-approval-komziftitm> ;
  schema:addressCountry "US" ;
  onco:cancers <https://onco.cc/cancers/aml/> ;
  onco:sections <https://onco.cc/fronts/epigenetics/> ;
  onco:drugs <https://onco.cc/drugs/ziftomenib/> ;
  onco:trials <https://onco.cc/trials/nct07007312/> .